The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having … Continued
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing … Continued
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell … Continued
(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor … Continued
We’re excited to announce that OCRFA’s new and refreshed website is live. The new site is reflective of the merger of Ovarian Cancer Research Fund and the Ovarian Cancer National … Continued
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive … Continued
A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose … Continued
(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with … Continued
Our #30DaysofTeal campaign spotlighted education and awareness facts about ovarian cancer. You, this amazing and strong community helped us educate 2.5 MILLION people about ovarian cancer throughout September. But awareness … Continued
Over 30,000 women and caregivers have found friends, support, strength and community on OCRFA’s Ovarian Cancer Community on Inspire. If you haven’t signed up yet, visit today to meet your … Continued
Get email updates about research news, action alerts, and ways to join the fight.
